Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Atul Prakash

Clinical Cardiac Electrophysiology Clifton, NJ Medical Doctor

NPI 1427085109 CMS profile 19553

905 Allwood Rd Ste 103, Clifton, NJ 07012

Open in the dashboard

General payments

$10,762

155 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,773 paid to institutions, not to them · program year 2019

Through program year 2025, Atul Prakash of Clifton, NJ is reported in the CMS Open Payments database as having received $10,762 across 155 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,773 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 36th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,754 30
2024 General $570 15
2023 General $4,513 12
2022 General $361 10
2021 General $897 31
2020 General $475 20
2019 General $2,193 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Atul Prakash
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Atul Prakash were reported at $1,754. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Atul Prakash Clinical Cardiac Electrophysiology median Middle half National median
2019 $2,193 $2,361 $585–$8,260 $163
2020 $475 $993 $247–$4,351 $114
2021 $897 $1,185 $326–$4,739 $132
2022 $361 $2,073 $554–$6,789 $149
2023 $4,513 $2,568 $759–$8,159 $160
2024 $570 $2,557 $703–$7,403 $164
2025 $1,754 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biotronik Inc. $5,288 11 payments
  2. Boston Scientific Corporation $2,410 26 payments
  3. Amgen Inc. $370 5 payments
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $314 11 payments
  5. E.R. Squibb & Sons, L.L.C. $308 24 payments
  6. Novartis Pharmaceuticals Corporation $259 16 payments
  7. Merck Sharp & Dohme Corporation $210 13 payments
  8. Biosense Webster, Inc. $207 3 payments
  9. Abiomed $164 4 payments
  10. Medtronic, Inc. $153 3 payments
  11. Other $1,081 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,049 147 payments
  2. Grant $4,000 1 payment
  3. Travel and Lodging $814 4 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $800 2 payments
  5. Education $99 1 payment
Products named General payments · program years 2019–2025
  1. Edora 8 DR-T $4,000 1 payment
  2. Solia $4,000 1 payment
  3. WATCHMAN Structural Heart $1,375 11 payments
  4. Repatha $370 5 payments
  5. LifeVest $314 11 payments
  6. WATCHMAN Pain Management $304 5 payments
  7. WATCHMAN FLX $288 3 payments
  8. ELIQUIS $276 22 payments
  9. WATCHMAN Access System $270 3 payments
  10. BIOMONITOR $267 3 payments
  11. Other $2,294 91 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 57 drugs

Part D claims

3,613

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$837,229

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

28.5%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 344 $354,187
Entresto Sacubitril/Valsartan Brand 148 $165,812
Xarelto Rivaroxaban Brand 80 $81,268
Jardiance Empagliflozin Brand 74 $61,139
Multaq Dronedarone Hcl Brand 18 $28,500
Repatha Sureclick Evolocumab Brand 21 $25,849
Farxiga Dapagliflozin Propanediol Brand 17 $18,931
Verquvo Vericiguat Brand 15 $16,407
Brilinta Ticagrelor Brand 20 $14,124
Praluent Pen Alirocumab Brand 23 $10,886

The 10 drugs with the highest cost, of 57 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$334,284

Medicare's payments for the services billed

Medicare patients

889

Average age 79

Services billed

4,608

442 women, 447 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 60%
Atrial fibrillation 57%
Diabetes 55%
Arthritis 50%
Heart failure 49%
Chronic kidney disease 37%
COPD 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $240
$240 21 —
VERQUVO
  • Merck Sharp & Dohme Corporation $52
$52 15 —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $31
$31 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $23
$23 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $14
$14 17 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

155 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record